Birch triterpenes - Generic Drug Details

What are the generic drug sources for birch triterpenes and what is the scope of patent protection?

Birch triterpenes is the generic ingredient in one branded drug marketed by Chiesi and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Birch triterpenes has eighty-eight patent family members in thirty-three countries.

Two suppliers are listed for this compound.

Summary for birch triterpenes

International Patents:	88
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	4
What excipients (inactive ingredients) are in birch triterpenes?	birch triterpenes excipients list
DailyMed Link:	birch triterpenes at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for birch triterpenes

Constraining patent/regulatory exclusivity:

TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for birch triterpenes

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey	PHASE4
Atabay Kimya Sanayi Ticaret A.S.	PHASE4
Jiangxi University of Traditional Chinese Medicine	NA

See all birch triterpenes clinical trials

US Patents and Regulatory Information for birch triterpenes

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes	11,266,660
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes	12,268,695
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes	8,828,444		Y

International Patents for birch triterpenes

Country	Patent Number	Title	Estimated Expiration
South Korea	20150029031	USE OF AN OLEOGEL CONTAINING TRITERPENE FOR HEALING WOUNDS
Russian Federation	2020125679	БЕТУЛИН-СОДЕРЖАЩИЕ ЭКСТРАКТЫ ИЗ БЕРЕЗОВОЙ КОРЫ И СОСТАВ НА ИХ ОСНОВЕ
Lithuania	C1758555
Japan	2016185996	表皮水泡症の創傷治癒剤 (AGENT FOR HEALING WOUNDS OF EPIDERMOLYSIS BULLOSA)

Supplementary Protection Certificates for birch triterpenes

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1758555	C20160023 00332	Estonia		PRODUCT NAME: BETULIIN;REG NO/DATE: EU/1/15/1069 18.01.2016
1758555	PA2016023,C1758555	Lithuania		PRODUCT NAME: BERZO ZIEVES EKSTRAKTAS; REGISTRATION NO/DATE: EU/1/15/1069/001 20160114
1758555	PA2016023	Lithuania		PRODUCT NAME: BERZO ZIEVES EKSTRAKTAS; REGISTRATION NO/DATE: EU/1/15/1069/001 20160114
1758555	132016000072478	Italy		PRODUCT NAME: ESTRATTO DI CORTECCIA DI BETULLA.(EPISALVAN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1069, 20160118

Birch triterpenes Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are Birch Triterpenes and Their Role in Pharmaceuticals?

Birch triterpenes are a class of bioactive compounds derived from the bark of birch trees, primarily Betula species. They include betulin, betulinic acid, and lupeol. These compounds exhibit anti-inflammatory, antiviral, anticancer, and hepatoprotective properties. Their integration into pharmaceutical and nutraceutical markets has increased, driven by their potential therapeutic applications.

How Are Birch Triterpenes Positioned in the Current Market?

The market for birch triterpenes is primarily driven by demand in dietary supplements, cosmeceuticals, and pharmaceutical research.

• Market Size and Growth: The global triterpenes market was valued at approximately $100 million in 2022, with expected compound annual growth rate (CAGR) around 7% through 2030.[1]
• Key Players: Companies like EpiBerry GmbH, Phytolab, and Bioalia produce extracts rich in betulin and betulinic acid. Large pharmaceutical firms are conducting R&D for drug candidates targeting cancer and viral infections.
• Application Segments: Supplements (nutraceuticals) account for over 60% of the market, with pharmaceutical applications comprising roughly 25%, and cosmeceuticals 15%.[2]

What Are the Main Challenges in Commercializing Birch Triterpenes?

The transition from discovery to market involves scientific, regulatory, and supply chain hurdles.

• Extraction and Purification: Efficient extraction from birch bark requires technologies like supercritical fluid extraction, which are cost-intensive. Purity levels directly impact regulatory approval chances.
• Supply Chain Constraints: Birch bark is a renewable source, but harvesting practices affect sustainability and supply stability. Limited cultivation hampers large-scale, consistent sourcing.
• Regulatory Environment: Scope varies by region. In the US, the FDA classifies betulin as Generally Recognized As Safe (GRAS) for use in supplements but not as a drug. Approval of birch triterpene-based drugs faces rigorous preclinical and clinical evaluation.

What Is the Financial Trajectory Expected for Birch Triterpene Development?

Investment flows into birch triterpenes are growing, driven by promising clinical data and expanding applications.

• Preclinical and Clinical Trials: Several candidates, particularly betulinic acid derivatives, are in preclinical stages. A limited number have advanced to phase I trials targeting cancers and viral infections.[3]
• Venture Capital and Funding: BioTech startups focusing on birch-derived compounds have attracted USD 50-100 million since 2019, with allocations toward extraction technologies, formulation, and clinical development.
• Partnerships and Licensing: Major pharma companies engage in licensing deals with smaller firms for specific compounds. These agreements typically involve upfront payments of USD 10-20 million plus milestone payments.

How Do Competitive and Regulatory Factors Impact Future Growth?

Market expansion depends on scientific validation, regulatory acceptance, and patent protection.

• Scientific Validation: Demonstration of efficacy and safety in clinical trials can elevate birch triterpenes from supplement ingredients to registered pharmaceuticals.
• Regulatory Approval: A clear pathway exists for botanical drugs in FDA’s Botanical Drug Development Program, potentially accelerating approval. Elsewhere, regulatory pathways are less defined, leading to market fragmentation.
• Patent Landscape: Patents cover extraction methods, formulations, and specific uses, providing commercial exclusivity. However, potential patent expiry within 10-15 years could introduce generic competition, reducing prices.

What Are Future Market Opportunities and Risks?

Opportunities:

• Expanding use in antiviral and anticancer therapies with ongoing clinical trials.
• Development of standardized extracts with consistent bioactivity.
• Increasing consumer acceptance of plant-based health products.

Risks:

• Scientific uncertainties regarding efficacy for some indications.
• Regulatory delays impacting market entry timelines.
• Scalability issues resulting from limited natural biomass and extraction costs.

Key Takeaways

• The birch triterpenes market is growing at a steady pace, driven by interest in natural therapeutics and the potential for drug development.
• Challenges in extraction, supply chain sustainability, and regulatory pathways hinder rapid commercialization.
• Early-stage clinical trials, licensing deals, and funding indicate promising financial trajectories.
• Market expansion will depend heavily on scientific validation and regulatory approval success.
• Competition will intensify as patent protections expire and generics enter the market.

FAQs

1. What is the primary therapeutic application of birch triterpenes?
They are researched mainly for anticancer, antiviral, anti-inflammatory, and hepatoprotective effects.

2. Can birch triterpenes be used in pharmaceutical drugs today?
Some extracts are used in dietary supplements, but approved drug formulations are limited to early clinical trials.

3. What is the commercial viability of betulin-based products?
Commercial viability hinges on scalable extraction processes and successful clinical validation, which are ongoing.

4. How sustainable is birch bark as a source?
While birch bark is renewable, overharvesting risks environmental sustainability. Cultivation and controlled harvesting are required for supply stability.

5. Are there regional differences in regulation?
Yes. The U.S. regulates botanical products through the FDA, where betulin is considered GRAS; elsewhere, regulatory pathways may vary, impacting market access.

---

Sources

1. MarketsandMarkets. "Triterpenes Market by Type, Application, and Region," 2022.
2. Grand View Research. "Global Nootropic Ingredients Market," 2021.
3. ClinicalTrials.gov. Search for betulin-based clinical trials, accessed 2023.